Search Results - "ROUDOT, ALICE"

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening by Ratziu, Vlad, Harrison, Stephen, Francque, Sven, Bedossa, Pierre, Lehert, Philippe, Serfaty, Lawrence, Romero-Gomez, Manuel, Boursier, Jérôme, Abdelmalek, Manal, Caldwell, Steve, Drenth, Joost, Anstee, Quentin, Hum, Dean, Hanf, Remy, Roudot, Alice, Megnien, Sophie, Staels, Bart, Sanyal, Arun

“…Background & Aims Elafibranor is an agonist of the peroxisome proliferator−activated receptor-α and peroxisome proliferator−activated receptor-δ. Elafibranor…”
Get full text

A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study by Harrison, Stephen A, Ratziu, Vlad, Boursier, Jérôme, Francque, Sven, Bedossa, Pierre, Majd, Zouher, Cordonnier, Geneviève, Sudrik, Fouad Ben, Darteil, Raphael, Liebe, Roman, Magnanensi, Jérémy, Hajji, Yacine, Brozek, John, Roudot, Alice, Staels, Bart, Hum, Dean W, Megnien, Sophie Jeannin, Hosmane, Suneil, Dam, Noémie, Chaumat, Pierre, Hanf, Rémy, Anstee, Quentin M, Sanyal, Arun J

“…Non-invasive tests that can identify patients with non-alcoholic steatohepatitis (NASH) at higher risk of disease progression are lacking. We report the…”
Get more information

Serum levels of miR-34a to rule-out NAFLD in healthy subjects and identify NAFLD patients with active NASH (NAS>= 4) and significant liver fibrosis (F >= 2) by Harrison, Stephen, Anstee, Quentin, Ratziu, Vlad, Bedossa, Pierre, Cordonnier, Genevieve, Majd, Zouher, Roudot, Alice, Sudrick, Fouad Ben, Dam, Noémie, Brozek, John, Birman, Pascal, Chaumat, Pierre, Staels, Bart, Hum, Dean, Hosmane, Suneil, Hanf, Remy, Sanyal, Arun

Get full text

AS102 - Serum levels of miR-34a to rule-out NAFLD in healthy subjects and identify NAFLD patients with active NASH (NAS>= 4) and significant liver fibrosis (F >= 2) by Harrison, Stephen, Anstee, Quentin, Ratziu, Vlad, Bedossa, Pierre, Cordonnier, Genevieve, Majd, Zouher, Roudot, Alice, Sudrick, Fouad Ben, Dam, Noémie, Brozek, John, Birman, Pascal, Chaumat, Pierre, Staels, Bart, Hum, Dean, Hosmane, Suneil, Hanf, Remy, Sanyal, Arun

Get full text

278-LB: Type 2 Diabetes (T2D) as a Risk Factor for NASH and Significant Liver Fibrosis (F>2) in an International Cohort of 2,363 Patients with Metabolic Steatosis by STAELS, BART, RATZIU, VLAD, SANYAL, ARUN J., FRANCQUE, SVEN, HARRISON, STEPHEN A., ROUDOT, ALICE, BROZEK, JOHN, HAJJI, YACINE, MEGNIEN, SOPHIE, HUM, DEAN W., BIRMAN, PASCAL, HANF, RéMY, CARIOU, BERTRAND

“…Background and Aim: T2D increases the prevalence of steatosis and steatohepatitis (NASH). The aim was to assess the relationship between T2D and two…”
Get full text

279-LB: NIS4, a Novel Blood Test, Can Identify "At-Risk" NASH (NAS>4 and Fibrosis>2) in T2D Patients by STAELS, BART, RATZIU, VLAD, FRANCQUE, SVEN, HARRISON, STEPHEN A., BEDOSSA, PIERRE, ROUDOT, ALICE, MAJD, ZOUHER, BROZEK, JOHN, BEN-SUDRIK, FOUAD, BIRMAN, PASCAL, HUM, DEAN W., HOSMANE, SUNEIL, CHAUMAT, PIERRE, HANF, RéMY, CARIOU, BERTRAND, SANYAL, ARUN

“…Background and Aim: T2D is an independent risk factor for the development of nonalcoholic steatohepatitis (NASH). Amongst NASH patients, those with elevated…”
Get full text

SAT-299-Assessment of NIS4 clinical utility for identification of patients with active NASH (NAS ≥ 4) and significant fibrosis (F ≥ 2) in patients at risk of NASH by Hanf, Remy, Chaumat, Pierre, Majd, Zouher, Cordonnier, Genevieve, Brozek, John, Praca, Emilie, Sudrik, Fouad Ben, Bedossa, Prof. Pierre, Anstee, Prof. Quentin M., Francque, Prof. Sven, Harrison, Prof. Stephen A., Ratziu, Prof. Vlad, Mégnien, Sophie, Roudot, Alice, Hosmane, Suneil, Hum, Dean W., Sanyal, Arun J.

Get full text